1. Introduction {#sec1}
===============

The cancer incidence and mortality have been increasing worldwide. Esophageal cancer (EC) is one of the most common cancers and remains the 4th leading cause of cancer death \[[@B1]\]. There are two major histologic types of EC: esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC). ESCC is the most common pathological type in China \[[@B2], [@B3]\]. However, the prognosis for patients with ESCC is still poor \[[@B3]\]. Therefore, assessing the prognostic factors in ESCC patients will become more and more important.

Recent reports revealed that inflammation plays an important role in cancer \[[@B4], [@B5]\]. Therefore, a series of inflammation-based biomarkers, such as C-reactive protein (CRP), neutrophil-to-lymphocyte ratio (NLR), and platelet-count-to-lymphocyte ratio (PLR), have been analysed in various cancers \[[@B6]--[@B11]\]. However, the prognostic values of these biomarkers in patients with ESCC remain uncertain \[[@B12]--[@B17]\]. In addition, most of these studies only evaluated one or two biomarkers without considering others. In the current study, therefore, we proposed a novel inflammation-based stage, named I stage (combination of CRP, NLR, and PLR), for predicting the prognosis for patients with resectable ESCC.

2. Patients and Methods {#sec2}
=======================

A retrospective analysis was conducted for patients with ESCC in our hospital from January 2005 to December 2008. Patients with ESCC were confirmed by histopathology. All patients underwent surgery with curative esophagectomy and standard lymphadenectomy. Patients who had received preoperative therapy were excluded. Patients with any form of acute infection or chronic inflammatory disease were also excluded. At last, 323 patients were enrolled in our study. In the current study, a cancer-specific survival (CSS) analysis was ascertained. The last follow-up was on 30 June 2013. This study was approved by the Ethical Committees of Zhejiang Cancer Hospital (Hangzhou, China). All patients were staged according to the 7th edition of the American Joint Committee on Cancer (AJCC) Cancer Staging \[[@B18]\].

Routine laboratory results (including CRP, neutrophil, lymphocyte, and platelet count) were extracted in retrospective medical records. The definitions of NLR and PLR were described as follows: NLR is neutrophil-to-lymphocyte ratio and PLR is platelet-count-to-lymphocyte ratio. The cut-off values for CRP, NLR, and PLR were 10 mg/L, 3.5, and 150 according to the previous studies \[[@B12], [@B13], [@B16], [@B17]\]. Therefore, the I stage was calculated as follows: patients with high levels of CRP (\>10 mg/L), NLR (\>3.5), and PLR (\>150) were defined as I3. Patients with two, one, or no abnormal value were defined as I2, I1, or I0, respectively.

2.1. Statistical Analysis {#sec2.1}
-------------------------

The 5-year CSS was analysed by the Kaplan-Meier method. Univariate and multivariate Cox analyses were performed to analyse the prognostic factors. Pearson correlation analyses were performed to analyse the correlation. Receiver operating characteristic (ROC) curves were plotted to determine the accuracy of CRP, NLR, and PLR. A *P* \< 0.05 was considered to be statistically significant. Statistical analyses were conducted with SPSS 17.0 (SPSS Inc., Chicago, IL, USA).

3. Results {#sec3}
==========

Clinicopathologic characters were shown in [Table 1](#tab1){ref-type="table"}. The mean CRP, NLR, and PLR were 9.7 ± 13.5 (mg/L), 3.3 ± 2.8, and 160.9 ± 70.6, respectively. The histograms of CRP, NLR, and PLR were shown in [Figure 1](#fig1){ref-type="fig"}. There were significant positive correlations in CRP and NLR (*r* = 0.258, *P* \< 0.001), CRP and PLR (*r* = 0.265, *P* \< 0.001), and NLR and PLR (*r* = 0.470, *P* \< 0.001) ([Figure 2](#fig2){ref-type="fig"}). ROC curves for CSS prediction were shown in [Figure 3](#fig3){ref-type="fig"}. The area under the curve (AUC) was 0.713 (95% CI: 0.653--0.772, *P* \< 0.001) for CRP, 0.650 (95% CI: 0.589--0.711, *P* \< 0.001) for NLR, and 0.685 (95% CI: 0.626--0.744, *P* \< 0.001) for PLR.

Of the 323 patients, 112 (34.7%) were allocated an I stage 0, 97 (30.0%) were allocated an I stage 1, 66 (20.4%) were allocated an I stage 2, and 48 (14.9%) were allocated an I stage 3, respectively. The relationships between the I stage and clinicopathological characteristics were shown in [Table 2](#tab2){ref-type="table"}. Our study demonstrated that I stage was associated with tumor length (*P* \< 0.001), perineural invasion (*P* = 0.043), T stage (*P* \< 0.001), N stage (*P* \< 0.001), and TNM stage (*P* \< 0.001). In addition, our study revealed that CRP, NLR, and PLR were significantly higher in patients with high I stage (*P* \< 0.001, [Figure 4](#fig4){ref-type="fig"}).

The 5-year CSS in patients with I0, I1, I2, and I3 was 50.0%, 30.9%, 18.2%, and 8.3%, respectively (*P* \< 0.001, [Figure 5](#fig5){ref-type="fig"}) (I0 versus I1, *P* = 0.002; I1 versus I2, *P* = 0.012; I2 versus I3, *P* = 0.020). In addition, our study revealed that patients with CRP (\>10.0 mg/L), NLR (\>3.5), or PLR (\>150) were significantly associated with decreased CSS, respectively (*P* \< 0.001). Then, we further stratified patients into different groups based on TNM stage. Our results demonstrated that I stage was also significantly correlated with CSS based on TNM stage ([Figure 6](#fig6){ref-type="fig"}).

Among the above variables, univariate analyses revealed that tumor length (*P* = 0.004), vessel involvement (*P* = 0.008), perineural invasion (*P* = 0.006), TNM stage (*P* \< 0.001), and I stage (*P* \< 0.001) were predictive of CSS ([Table 3](#tab3){ref-type="table"}). In multivariate analyses, we demonstrated that I stage was an independent prognostic factor in patients with resectable ESCC (*P* \< 0.001) ([Table 4](#tab4){ref-type="table"}).

4. Discussion {#sec4}
=============

In the current study, we initially proposed a novel inflammation-based prognostic system, named I stage (combination of CRP, NLR, and PLR), in patients with resectable ESCC. Our study revealed that I stage was associated with tumor length, perineural invasion, and TNM stage. In multivariate analyses, we revealed that I stage is a useful predictor of postoperative CSS in patients with resectable ESCC (*P* \< 0.001).

Several hematological biomarkers have shown prognostic values in cancers. In particular, the CRP has been well validated. CRP is a representative acute-phase reactant for inflammation \[[@B19]\]. Recently, several previous studies have shown that CRP is associated with prognosis in several cancers, including ECs \[[@B6], [@B8]--[@B12]\]. In our study, patients with CRP ≤ 10.0 mg/L had a significantly better 5-year CSS than patients with CRP \> 10.0 mg/L (39.2% versus 17.1%, *P* \< 0.001). However, CRP was not an independent prognostic factor in multivariate analyses (*P* = 0.493).

The prognostic values of NLR and PLR in patients with EC remain uncertain. Several reports demonstrated that NLR is an independent prognostic factor in patients with EC \[[@B14], [@B15]\]. However, Rashid et al. \[[@B13]\] and Dutta et al. \[[@B16]\] revealed that NLR does not correlate with prognosis for patients with EC. Moreover, there have been few studies regarding PLR in EC patients. Dutta et al. \[[@B16]\] demonstrated that PLR does not correlate with prognosis in patients with EC. A retrospective study by Liu et al. \[[@B20]\] on 326 ESCC patients revealed PLR to be a potential prognostic factor. In our study, NLR and PLR were correlated with survival; however, NLR and PLN were not independent prognostic factors in multivariate analyses.

At present, the prognosis of cancer is commonly based on the TNM staging system \[[@B21], [@B22]\]. Inflammation plays an important role in cancer. Therefore, in our study, we proposed a novel inflammation-based prognostic system (I stage) in resectable ESCC patients. A significant association was found between the I stage and clinical characteristics. In multivariate analyses, we revealed that I stage is a useful predictor of postoperative CCS in patients with resectable ESCC (*P* \< 0.001). It may well be that the influence of I stage on the subgroup with TNM stage is important for the understanding of its role in patients with ESCC. Our results demonstrated that I stage was also significantly correlated with CSS based on TNM stage.

Limitations should be acknowledged. Firstly, our study was a retrospective study. Secondly, we excluded patients with neoadjuvant treatment, which may have influenced the results. Neoadjuvant treatment will inevitably have an impact on the systemic inflammation. Thus, evaluation of I stage in neoadjuvant therapy does not reflect the baseline impact of systemic inflammation for ESCC patients. Therefore, larger prospective studies will need to be performed to confirm these preliminary results.

In summary, there was a significant association between the I stage (combination of CRP, NLR, and PLR) and clinical characteristics. Based on the results of the current study, we believe that I stage is a novel and useful predictive factor for CSS in patients with resectable ESCC.
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![The histograms of the CRP (a), NLR (b), and PLR (c).](MI2016-5396747.001){#fig1}

![Pearson correlation analysis. Positive correlations in CRP and NLR (*r* = 0.258, *P* \< 0.001; (a)), CRP and PLR (*r* = 0.265, *P* \< 0.001; (b)), and NLR and PLR (*r* = 0.470, *P* \< 0.001; (c)).](MI2016-5396747.002){#fig2}

![ROC curves for CSS prediction. The area under the curve (AUC) was 0.713 (95% CI: 0.653--0.772, *P* \< 0.001) for CRP, 0.650 (95% CI: 0.589--0.711, *P* \< 0.001) for NLR, and 0.685 (95% CI: 0.626--0.744, *P* \< 0.001) for PLR.](MI2016-5396747.003){#fig3}

![The CRP (a), NLR (b), and PLR (c) were significantly higher in patients with high I stage (*P* \< 0.001). The "∗" and "•" were created by SPSS statistical software.](MI2016-5396747.004){#fig4}

![The 5-year CSS in patients with I0, I1, I2, and I3 was 50.0%, 30.9%, 18.2%, and 8.3%, respectively (*P* \< 0.001) (I0 versus I1, *P* = 0.002; I1 versus I2, *P* = 0.012; I2 versus I3, *P* = 0.020).](MI2016-5396747.005){#fig5}

![The predictive values of I stage were significant in patients based on TNM stage. TNM I stage (*P* = 0.035, (a)), TNM II stage (*P* = 0.028, (b)), and TNM III stage (*P* \< 0.001, (c)).](MI2016-5396747.006){#fig6}

###### 

Clinicopathological characteristics for patients with ESCC.

                                 Cases (*n*, %)
  ------------------------------ ----------------
  Age (years, mean ± SD)         59.1 ± 7.9
  Gender                          
   Female                        42 (13.0)
   Male                          281 (87.0)
  Tumor length (cm, mean ± SD)   4.3 ± 1.9
  Tumor location                  
   Upper                         17 (5.3)
   Middle                        151 (46.7)
   Lower                         155 (48.0)
  Differentiation                 
   Good                          44 (13.6)
   Moderate                      216 (66.9)
   Poor                          63 (19.5)
  T grade                         
   T1                            55 (17.0)
   T2                            55 (17.0)
   T3                            179 (55.4)
   T4                            34 (10.6)
  N stage                         
   N0                            174 (53.9)
   N1                            87 (26.9)
   N2                            37 (11.5)
   N3                            25 (7.7)
  TNM stage                       
   I                             81 (25.1)
   II                            104 (32.2)
   III                           138 (42.7)
  I stage                         
   I0                            112 (34.7)
   I1                            97 (30.0)
   I2                            66 (20.4)
   I3                            48 (14.9)
  CRP (mg/L, mean ± SD)          9.7 ± 13.5
  NLR (mean ± SD)                3.3 ± 2.8
  PLR (mean ± SD)                160.9 ± 70.6

###### 

The relationship between I stage and clinicopathological characteristics.

                        I stage 0   I stage 1   I stage 2   I stage 3   *P* value
  --------------------- ----------- ----------- ----------- ----------- -----------
  Age (years)                                                           0.817
   ≤60                  66          58          37          25          
   \>60                 46          39          29          23          
  Gender                                                                0.375
   Female               18          14          5           5           
   Male                 94          83          61          43          
  Tumor length (cm)                                                     \<0.001
   ≤3                   45          31          9           4           
   \>3                  67          66          57          44          
  Tumor location                                                        0.488
   Upper                8           4           1           4           
   Middle               51          49          28          23          
   Lower                53          44          37          21          
  Vessel involvement                                                    0.385
   Negative             99          79          54          38          
   Positive             13          18          12          10          
  Perineural invasion                                                   0.043
   Negative             98          70          52          40          
   Positive             14          27          14          8           
  Differentiation                                                       0.310
   Good                 17          10          12          5           
   Moderate             80          65          41          30          
   Poor                 15          22          13          13          
  T stage                                                               \<0.001
   T1                   33          18          3           1           
   T2                   23          14          11          7           
   T3                   50          58          42          29          
   T4                   6           7           10          11          
  N stage                                                               \<0.001
   N0                   71          55          32          16          
   N1                   30          30          12          15          
   N2                   6           9           12          10          
   N3                   5           3           10          7           
  TNM stage                                                             \<0.001
   I                    46          21          9           5           
   II                   31          41          22          10          
   III                  35          35          35          33          

###### 

Univariate analyses for patients with ESCC.

                        5-year CSS (%)   *P* value   HR (95% CI)            *P* value
  --------------------- ---------------- ----------- ---------------------- -----------
  Age (years)                            0.978                              0.978
   ≤60                  30.1                         1.000                   
   \>60                 33.6                         0.996 (0.762--1.302)    
  Gender                                 0.322                              0.327
   Female               38.1                         1.000                   
   Male                 30.6                         1.227 (0.815--1.848)    
  Tumor length (cm)                      0.003                              0.004
   ≤3                   41.6                         1.000                   
   \>3                  27.8                         1.580 (1.157--2.157)    
  Tumor location                         0.556                              0.564
   Upper                41.2                         1.000                   
   Middle               33.1                         0.735 (0.385--1.404)   0.351
   Lower                29.0                         0.908 (0.693--1.190)   0.483
  Differentiation                        0.198                              0.207
   Good                 38.6                         1.000                   
   Moderate             31.0                         1.185 (0.786--1.786)   0.417
   Poor                 28.6                         1.504 (0.933--2.424)   0.098
  Vessel involvement                     0.007                              0.008
   Negative             34.1                         1.000                   
   Positive             18.9                         1.577 (1.129--2.202)    
  Perineural invasion                    0.005                              0.006
   Negative             35.0                         1.000                   
   Positive             17.5                         1.551 (1.135--2.119)    
  TNM stage                              \<0.001                            \<0.001
   I                    51.9                         1.000                   
   II                   32.7                         1.878 (1.269--2.780)   0.002
   III                  18.8                         2.943 (2.039--4.248)   \<0.001
  I stage                                \<0.001                            \<0.001
   I0                   50.0                         1.000                   
   I1                   30.9                         1.696 (1.189--2.420)   0.004
   I2                   18.2                         2.676 (1.837--3.900)   \<0.001
   I3                   8.3                          4.372 (2.924--6.536)   \<0.001
  Adjuvant therapy                       0.398                              0.402
   No                   32.0                         1.000                   
   Yes                  30.6                         1.130 (0.849--1.504)    
  CRP (mg/L)                             \<0.001                            \<0.001
   ≤10.0                39.2                         1.000                   
   \>10.0               17.1                         2.217 (1.692--2.906)    
  NLR                                    \<0.001                            \<0.001
   ≤3.5                 39.0                         1.000                   
   \>3.5                17.7                         1.925 (1.471--2.519)    
  PLR                                    \<0.001                            \<0.001
   ≤150                 43.9                         1.000                   
   \>150                17.3                         2.260 (1.729--2.955)    

###### 

Multivariate analyses for patients with ESCC.

                        HR (95% CI)            *P* value
  --------------------- ---------------------- -----------
  Tumor length (cm)                            0.603
   ≤3                   1.000                   
   \>3                  1.075 (0.818--1.412)    
  Vessel involvement                           0.742
   Negative             1.000                   
   Positive             1.060 (0.747--1.505)    
  Perineural invasion                          0.077
   Negative             1.000                   
   Positive             1.341 (0.968--1.857)    
  TNM stage                                    \<0.001
   I                    1.000                   
   II                   1.586 (1.048--2.400)   0.029
   III                  2.220 (1.456--3.384)   \<0.001
  I stage                                      \<0.001
   I0                   1.000                   
   I1                   1.543 (1.076--2.214)   0.018
   I2                   2.356 (1.602--3.466)   \<0.001
   I3                   3.594 (2.363--5.467)   \<0.001
  CRP (mg/L)                                   0.493
   ≤10.0                1.000                   
   \>10.0               1.151 (0.770--1.719)    
  NLR                                          0.786
   ≤3.5                 1.000                   
   \>3.5                1.050 (0.740--1.488)    
  PLR                                          0.065
   ≤150                 1.000                   
   \>150                1.440 (0.978--2.121)    
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